AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03169387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
Study NCT03169387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
Study NCT01777854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
Study NCT01777854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
Study NCT03335462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral injections
Description: Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
Study NCT03335462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan will be performed as the needles are kept in their position after injecting the contrast
Study NCT05029765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates
Study NCT05029765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates
Study NCT05029765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Healthy diet (WHO recommendations)
Description: Recommendations according to WHO
Study NCT05029765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05029765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biopolis-MIX42
Description: Biopolis-MIX42: a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
Study NCT01280279 — intervention group
Intervention type: OTHER
Intervention: education for behavioral modification
Description: a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
Study NCT02833610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Q4W
Study NCT04528836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 (Formerly known as IACS-15509)
Description: oral capsules
Study NCT04322682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
Study NCT04322682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
Study NCT01221987 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical sampling
Description: Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
Study NCT01221987 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion
Study NCT02196649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Clip
Study NCT05283317 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
Study NCT01930110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minute exercise
Description: Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
Study NCT01930110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40-minute interval exercise
Description: Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
Study NCT01641250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5429083
Description: Multiple escalating doses
Study NCT01641250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
Study NCT01270126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transorbital alternating current stimulation
Description: Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
Study NCT02158676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Fructooligosaccharides
Study NCT02158676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
Study NCT02158676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 100 mg BID for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 100 mg BID for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 300 mg BID for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 300 mg BID for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 600 mg BID for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 600 mg BID for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 1200 mg QD for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 1200 mg QD for 14 days
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study NCT00990990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 300 mg QD for 4 days (open label)
Study NCT03628209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
Study NCT03628209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
Study NCT03926078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D optical surface image
Description: 3D optical surface images will be acquired and used to calculate the EHI
Study NCT03628209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Treatment Surgery
Description: Resection surgery at end of Cycle 1 treatment, day 28-35.
Study NCT03926078 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Chest radiography
Description: Chest radiographies will be acquired and used to calculated the HI and EHI
Study NCT03926078 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CT scan
Description: CT scans will be acquired and used to calculate the HI and EHI
Study NCT04098874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Extended Release Oral Tablet
Description: 12 weeks postpartum of blinded study medication
Study NCT04098874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 12 weeks postpartum of blinded placebo
Study NCT03985592 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Intervention description provided in elaboration on arms of the study.
Study NCT03985592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Intervention description provided in elaboration on arms of the study.
Study NCT02251587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Management Program
Description: Standard Diet program based on diet and exercise.
Study NCT02251587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensible Weigh Program
Description: Weight loss program designed for low income women.
Study NCT01977326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: basic counselling by lay-health workers
Description: 6 sessions of manual based counselling by trained lay health workers
Study NCT01977326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 3 monthly phone calls by trained lay health workers (without counselling)
Study NCT03198299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEI BIN insoles
Description: wearing insoles for 12 weeks
Study NCT02405611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral
Description: The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
Study NCT04288635 — intervention group
Intervention type: BIOLOGICAL
Intervention: Whole blood samples
Description: Whole blood samples at admission, from day one to three after admission
Study NCT02515760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration from the iliac crest
Study NCT02515760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illinois bone marrow aspiration neddle
Study NCT02738866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
Study NCT02738866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
Study NCT03941080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fecal sample
Description: patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
Study NCT03941080 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
Study NCT03941080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: 4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
Study NCT03444428 — intervention group
Intervention type: OTHER
Intervention: Non Invasive Ventilation
Description: Assessments for those participants who are being set up onto NIV
Study NCT03444428 — intervention group
Intervention type: OTHER
Intervention: Without Non Invasive Ventilation
Description: Assessments for those participants who are not being set up onto NIV
Study NCT03642964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTC-501
Description: pramipexole IR, given with ondansetron
Study NCT03642964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTC-501
Description: pramipexole IR, given with ondansetron
Study NCT01809301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niaspan
Study NCT01809301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIA-662
Study NCT02273063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Up to 40 sessions of TMS delivered with the first 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper schedule over 3 weeks. Treatment is adjunct to ongoing stable pharmacotherapy.
Study NCT00656292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: 40 mg po/nasogastric tube (NG) every day for 6 days
Study NCT00656292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 pill po/NG every day x 6 days
Study NCT01677572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
Description: Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
Study NCT02118220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Concussion Questionnaire
Study NCT03584451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation sport
Description: rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
Study NCT04464928 — intervention group
Intervention type: OTHER
Intervention: Facebook Advertisements
Description: Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
Study NCT04464928 — intervention group
Intervention type: OTHER
Intervention: Google Advertisements
Description: Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
Study NCT04617639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
Study NCT04617639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
Study NCT04617639 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Observation group
Description: Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
Study NCT02430194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor
Study NCT00776984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
Study NCT00728832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DepoDur (extended-release epidural morphine)
Description: DepoDur with on demand boluses of IV fentanyl PCA
Study NCT00728832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur (extended-release epidural morphine)
Description: DepoDur with on demand boluses of IV fentanyl PCA
Study NCT01856647 — intervention group
Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy (fat biopsy)
Description: An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.
Study NCT01209936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D2O
Description: All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
Study NCT01677572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
Description: Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
Study NCT01677572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
Study NCT01779128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-CT